Home » Stocks » TLIS

Talis Biomedical Corporation (TLIS)

Stock Price: $9.76 USD -0.02 (-0.19%)
Updated Jun 21, 2021 1:02 PM EDT - Market open
Market Cap 250.74M
Revenue (ttm) 17.54M
Net Income (ttm) n/a
Shares Out 13.11M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $9.76
Previous Close $9.78
Change ($) -0.02
Change (%) -0.19%
Day's Open 9.89
Day's Range 9.51 - 9.95
Day's Volume 142,446
52-Week Range 9.43 - 33.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

1 month ago - GlobeNewsWire

According to Insider Cluster Buys, a Premium feature of GuruFocus, four stocks with a high number of unique insider buys during February and March are Camden National Corp. (NASDAQ:CAC), Talis Biomedica...

Other stocks mentioned: CAC, MLVF, SGFY
3 months ago - GuruFocus

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, NEXI ...
4 months ago - Benzinga

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

4 months ago - GlobeNewswire

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

4 months ago - GlobeNewswire

Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

4 months ago - NASDAQ

Talis Biomedical Corporation has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About TLIS

Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care. We are developing the Talis One platform, a sample-to-answer, cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central labora... [Read more...]

Industry
Medical Devices
IPO Date
Feb 12, 2021
CEO
Brian Coe
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
TLIS
Full Company Profile

Financial Performance

In 2020, TLIS's revenue was $10.94 million, an increase of 175.03% compared to the previous year's $3.98 million. Losses were -$91.13 million, 231.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TLIS stock is "Buy." The 12-month stock price forecast is 14.00, which is an increase of 43.43% from the latest price.

Price Target
$14.00
(43.43% upside)
Analyst Consensus: Buy